

# ANTI DIABETIC MEDICATIONS

BENEFITS, COSTS AND  
ADVERSE EFFECTS

---

Yassin Mustafa, MD  
KPN Endocrinology



# No disclosure

---

# Objectives

---

- Recognize all available medical treatment options for diabetes
- Individualize treatment and glycemic target based on patient factors
- Should be able to switch to more affordable treatment regimens when cost is an issue

# Case

---

- 74 y/o male of medical history of osteoporosis, HTN, CKD
- T2DM for more than 15 years
- Admitted to hospital with hyperglycemia and urinary incontinence
- Patient reports that he has not been taking his medication for about 3 weeks because of the cost
- On admission his RBG was 520 mg/dl and A1C 11.6

# Home medications

---

Tresiba 70 units daily

Tradjenta 5 mg daily

Actos 45 mg daily

patient was previously on Levemir , then switched to Tresiba, he recalls that he was switched from metformin but to Tradjenta because its safer for kidneys. He also reports that he was on glimepiride long time ago but not sure why was discontinued. No hx of severe hypoglycemia

NKDA

# Hospital course

---

Patient was mentally alert, was found to have UTI, admitted for IV antibiotics and rehydration, oral medication were discontinued, started on lantus 30 units and Novolog 6 units before meals in addition to correction

After 2 days patient is stable and ready for discharge

His BG was well controlled on the current insulin regimen

BMP: BG 148, BUN 26, Cr 1.5 eGFR 45

# What would be the most appropriate discharge regimen

---

1. Continue Tresiba, Tradjenta and Actos and ask the patient to see his PCP ASAP
2. d/c Tresiba, but continue Tradjenta and Actos
3. d/c Tresiba, Tradjenta and Actos, start Novolog SS
4. d/c Tresiba, Tradjenta and Actos, start Novolin N and metformin
5. d/c Tresiba, Tradjenta and Actos, start Novolin mix 70/30 and glimepiride

# The Staggering Costs of Diabetes

## GROWING EPIDEMIC

Diabetes affects  
**30 million**  
children and adults  
in the U.S.



That's  
**1 in 11**  
Americans.



**84 million** Americans  
have prediabetes and are at risk  
for developing type 2 diabetes.

**90% of them don't know**  
they have it.



Every **21 seconds**  
someone in the  
U.S. is diagnosed  
with diabetes.

## HUMAN COSTS

African Americans and  
Hispanics are over  
**50%**  
more likely to have diabetes  
than non-Hispanic whites.

People with diabetes are at higher risk of serious health complications:



STROKE



BLINDNESS



KIDNEY  
DISEASE



HEART  
DISEASE



LOSS OF  
TOES, FEET,  
OR LEGS

## ECONOMIC COSTS



The total cost of diabetes  
and prediabetes in the U.S. is  
**\$322 billion.**



The average price of  
insulin increased nearly **3x**  
between 2002 and 2013.



People with diabetes have  
health care costs  
**2.3x greater**  
than those  
without diabetes.

Learn more at [diabetes.org](http://diabetes.org)

 American  
Diabetes  
Association.





# Classes of medications

---

Metformin

Sulfonylureas SU

Meglitinides GLN

Thiazolidindions TZD

Alfa glucosidase inhibitors AG-i

GLP-1 agonist

DPP-4 inhibitors

SGLT-2 inhibitors

Bromocriptin

Colesevelam

Insulin

Pramlintide



## Glycemic Recommendations for Nonpregnant Adults with Diabetes

---

|  |   |
|--|---|
| <b>A1C</b>   | <b>&lt;7.0%*</b><br><b>(&lt;53 mmol/mol)</b>      |
| <b>Preprandial capillary plasma glucose</b>        | <b>80–130 mg/dL*</b><br><b>(4.4–7.2 mmol/L)</b>   |
| <b>Peak postprandial capillary plasma glucose†</b> | <b>&lt;180 mg/dL*</b><br><b>(&lt;10.0 mmol/L)</b> |


\* Goals should be individualized.

† Postprandial glucose measurements should be made 1–2 hours after the beginning of the meal.



# Target individualization

Approach to management of hyperglycemia:





# Metformin

---

- The first choice for oral treatment of type 2 diabetes.
- Glycemic efficacy: 1-1.5%
- Cost: (\$)
- No hypoglycemia or weight gain
- Gastrointestinal side effects with initiation and high doses
- B12 deficiency is often overlooked
- Lactic acidosis is exceedingly rare
- Contraindications: GFR<30, decompensated CHF, critical illness



# Sulfonylureas

---

- Long acting: Glimepiride and Glyburide and Short acting: glipizide
- Glycemic efficacy: 1-2%
- Cost: (\$)
- Side effects includes hypoglycemia and weight gain
- Hypoglycemia risk higher with long acting
- Gliclazide or Glimipride do not appear to be associated with increased CV risk



# Meglitinides

---

- Repaglinide (Prandin) and nateglinide (Starlix) are short-acting hypoglycemics
- Glycemic efficacy: 0.6-2.1%
- Cost (\$\$)
- Mechanism of action is similar to the sulfonylureas but Less risk of hypoglycemia.
- Useful for patient with allergy to SFU
- Repaglinide is principally metabolized by the liver



# Thiazolidinediones

---

- Rosiglitazone (avandia) and pioglitazone (Actos)
- Glycemic efficacy: 0.5-1.4 %
- Cost (\$\$)
- Side effect: Fluid retention: prominent with concomitant insulin therapy
- Rosiglitazone might be associated with increased CV risk
- Contraindicated in NYHA III CHF
- Concerns: Macular edema, Osteoporosis, bladder cancer



# Alpha-glucosidase inhibitors

---

- Acarbose and miglitol
- Glycemic efficacy: 0.4-0.9%
- Cost (\$\$)
- No hypoglycemia
- Side effects : flatulence and diarrhea





# GLP-1 agonists

---

- Injectable Liraglutide (Victoza), Exenatide (Bydureon), dulaglutide (Trulicity), Lixisenatide (soliqua)
- Glycemic efficacy: 1%
- Cost (\$\$\$)
- Benefits: weight reduction (approximately 1.5 to 2.5 kg over 30 week)
- (Liraglutide) appears to decrease macrovascular and microvascular complications
- Side effect: Nausea, vomiting and diarrhea
- Contraindications: h/o pancreatitis, medullary thyroid cancer, gastroparesis
- Semaglutide : CV benefits



# DPP-4 inhibitors

---

- Sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), and alogliptin (Nesina)
- Glycemic efficacy: 0.4-0.8%
- Cost (\$\$\$)
- No weight gain or hypoglycemia
- Well tolerated
- ? Acute pancreatitis
- Cases of hepatic dysfunction (liver enzyme elevations, hepatitis) with alogliptin
- Linagliptin metabolized by liver



# SGLT2-inhibitors

---

- Dapagliflozin (Farxiga), canagliflozin (Invokana) and empagliflozin (Jardiance)
- Glycemic efficacy: 0.4-1.1%
- Cost (\$\$\$)
- Benefits: Lowers systolic BP, Weight loss, No hypoglycemia
- Empagliflozin and canagliflozin appear to improve CV outcome
- Sotagliflozin for ? T1DM
- Side effect: Increased incidence of vulvovaginal candidiasis, genital infection and UTI
- Risks: Euglycemic DKA, risk of amputation with canagliflozin



# Colesevelam

---

- Welchol is bile acid sequestrant that lowers (LDL)
- Glycemic efficacy: 0.5%
- Cost (\$\$\$\$)
- Mechanism to improve glycemic control is uncertain.
- Side effects can include constipation, nausea, and dyspepsia.




# Bromocriptine

---

- (Cycloset) short acting bromocriptine
- Glycemic efficacy: 0.5%
- Cost (\$\$\$\$)
- The mechanism of action in reducing blood sugar is unknown.
- Common side effects include nausea, vomiting, dizziness, and headache.



# Insulin preparations





# Basal INSULIN

---

- T1DM: TDD 0.5 units/kg/day, 40% basal, 60% prandial
- T2DM: Add on therapy or starting, 10 U or 0.1-0.2 U/kg administered at bedtime to be titrated
  
- (\$\$\$) Analog long glargine (Lantus, Basaglar), detemir (Levemir), degludec (Tresiba) lower risk of hypoglycemia
  
- (\$) Human Intermediate (NPH) Novolin N : twice daily, hypoglycemia



# BOLUS INSULIN

---

- T1DM: TDD 0.5 units/kg/day, 40% basal, 60% prandial
- T2DM: Add on therapy or starting, 6 units before 1-3 meals to be titrated
- \$\$\$ Analog rapid aspart (Novolog), lispro (Humalog), glulisine (Apidra) : 5-10 mins before meals.
- \$ Human Short regular (Novolin R) : 30 mins before meals
- Ultra Rapid analog Fiasp





# Premixed insulin

---

- Not recommended for T1DM
- Convenient with less injections per day
- Difficult to titrate and needs consistent meal plan and timing
- Premixed insulin may be administered at the largest meal once daily or at the 2 largest meals twice daily.
- (\$\$\$) Analog Intermediate (NPL, NPA) + rapid lispro (Humalog mix), aspart (Novolog mix) different 70/30, 75/25, 50/50
- (\$) Human Intermediate NPH + regular 70/30 Novolin mix
- Analog long Degludec + rapid aspart (Ryzodeg)
- Switching from basal use 1:1 ratio, from basal/bolus decrease TTD by 20% , then split 50/50 vs 70/30 with breakfast and dinner to be titrated separately



# U-500

---

- Concentrated
- Available in vials and pens
- Cost (\$\$)
- Severe insulin resistance: > 200 units per day or 3 U/kg/day
- TTD 60/40 before breakfast and dinner
- > 300 U/day = 40/30/30 before meals



# Inhaled insulin

---

- Ultra rapid Afrezza
- benefits: Needle phobia
- Cost (\$\$\$)
- Side effects includes cough and reactive airway disease
- Contraindicated in chronic lung diseases and in smokers
- Needs PFT monitoring



# Pramlintide

---

- Pramlintide (Symlin) is a synthetic analog of amylin that reduces postprandial blood glucose by slowing gastric emptying and promoting satiety
- Pramlintide is only approved for use in patients also taking prandial insulin to control weight
- Cost (\$\$\$\$\$)

|                           | \$4, 30-day Supply | \$10, 90-day Supply | Other |
|---------------------------|--------------------|---------------------|-------|
| Glimepiride 1mg           | 30 tablets         | 90 tablets          | -     |
| Glimepiride 2mg           | 30 tablets         | 90 tablets          | -     |
| Glimepiride 4mg           | 30 tablets         | 90 tablets          | -     |
| Glipizide 5mg             | 30 tablets         | 90 tablets          | -     |
| Glipizide 10mg*           | 60 tablets         | 180 tablets         | -     |
| Glyburide 2.5mg           | 30 tablets         | 90 tablets          | -     |
| Glyburide 5mg (blue)      | 30 tablets         | 90 tablets          | -     |
| Glyburide 5mg (green)     | 30 tablets         | 90 tablets          | -     |
| Glyburide, micronized 3mg | 30 tablets         | 90 tablets          | -     |
| Glyburide, micronized 6mg | 30 tablets         | 90 tablets          | -     |
| Metformin 500mg           | 60 tablets         | 180 tablets         | -     |
| Metformin 850mg           | 60 tablets         | 180 tablets         | -     |
| Metformin 1000mg*         | 60 tablets         | 180 tablets         | -     |
| Metformin 500mg ER*       | 60 tablets         | 180 tablets         | -     |



# Novolin N

Novolin N (human insulin) is an intermediate-acting t including diabetes type 1 and diabetes type 2. Novoli any insulin brand, but less expensive biosimilar versi

Check our savings tips for co-pay cards, assistance Medicare and insurance plans.

## Prescription Settings

brand vial 10ml of 100 units/ml

- Prescription Settings
- Prices
- Medicare
- Savings Tips 2
- Drug Info
- Side Effects
- Images
- Latest News 6

**Actos Pioglitazone**

PIOGLITAZONE helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise. The lowest GoodRx price for the most common version of pioglitazone is FREE, 100% off the average retail price of \$228.13. Compare glitazones.

Prescription Settings generic tablet 30mg 30 tablets SAVE SHARE

Prices and coupons for 30 tablets of pioglitazone 30mg

Lowest prices near **Miamisburg, OH** Hide mail order Prescription is for a pet

**GoodRx Gold** Pay Just \$8.75 with GoodRx Gold Save even more on your family's prescriptions at **Kroger, Albertsons, Safeway** and other nearby pharmacies. [LEARN MORE](#)

**Sams Club** **Free** with membership [MORE INFO](#)

**Kroger Pharmacy** \$71 est cash price **\$12.10** with free coupon [GET FREE COUPON](#)

**Cloud Accounting Built for Nonprofits** **Financial Edge NXT** **blackbaud** [Learn more](#)



# Prandin Repaglinide

REPAGLINIDE helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise. The lowest GoodRx price for the most common version of repaglinide is around \$31.83, 88% off the average retail price of \$278.67. Compare glinides.

## Prescription Settings


generic tablet 1mg 90 tablets SAVE SHARE

Prices and coupons for 90 tablets of repaglinide 1mg

Lowest prices near **Miamisburg, OH** Hide mail order Prescription is for a pet

**Meijer Pharmacy** **\$31.83** with free coupon [GET FREE COUPON](#)

**Kroger Pharmacy** **\$32.53** with free coupon [GET FREE COUPON](#)



# Acarbose Generic Precose

ACARBOSE helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise. The lowest GoodRx price for the most common version of acarbose is around \$10.00, 87% off the average retail price of \$78.42. Compare alpha glucosidase inhibitors.

## Prescription Settings

generic tablet 25mg 90 tablets SAVE SHARE

Prices and coupons for 90 tablets of acarbose 25mg

Lowest prices near **Miamisburg, OH** Hide mail order Prescription is for a pet

**GoodRx Gold** Pay Just \$28.00 with GoodRx Gold Save even more on your family's prescriptions at **Kroger, Albertsons, Safeway** and other nearby pharmacies. [LEARN MORE](#)

**Sams Club** **\$10.00** with membership [MORE INFO](#)

**Meijer Pharmacy** **\$28.18** with free coupon [GET FREE COUPON](#)

## Start with Monotherapy unless:

A1C is greater than or equal to 9%, **consider Dual Therapy.**

A1C is greater than or equal to 10%, blood glucose is greater than or equal to 300 mg/dL, or patient is markedly symptomatic, **consider Combination Injectable Therapy** (See Figure 8.2).

### Monotherapy

#### Metformin

### Lifestyle Management

|                     |                    |
|---------------------|--------------------|
| <b>EFFICACY*</b>    | high               |
| <b>HYPO RISK</b>    | low risk           |
| <b>WEIGHT</b>       | neutral/loss       |
| <b>SIDE EFFECTS</b> | GI/lactic acidosis |
| <b>COSTS*</b>       | low                |

If A1C target not achieved after approximately 3 months of monotherapy, proceed to 2-drug combination (order not meant to denote any specific preference — choice dependent on a variety of patient- & disease-specific factors):

### Dual Therapy

#### Metformin +

### Lifestyle Management

|                     | Sulfonylurea  | Thiazolidinedione | DPP-4 inhibitor | SGLT2 inhibitor      | GLP-1 receptor agonist | Insulin (basal) |
|---------------------|---------------|-------------------|-----------------|----------------------|------------------------|-----------------|
| <b>EFFICACY*</b>    | high          | high              | intermediate    | intermediate         | high                   | highest         |
| <b>HYPO RISK</b>    | moderate risk | low risk          | low risk        | low risk             | low risk               | high risk       |
| <b>WEIGHT</b>       | gain          | gain              | neutral         | loss                 | loss                   | gain            |
| <b>SIDE EFFECTS</b> | hypoglycemia  | edema, HF, fxs    | rare            | GU, dehydration, fxs | GI                     | hypoglycemia    |
| <b>COSTS*</b>       | low           | low               | high            | high                 | high                   | high            |

If A1C target not achieved after approximately 3 months of dual therapy, proceed to 3-drug combination (order not meant to denote any specific preference — choice dependent on a variety of patient- & disease-specific factors):

### Triple Therapy

#### Metformin +

### Lifestyle Management

| Sulfonylurea +          | Thiazolidinedione +     | DPP-4 inhibitor +       | SGLT2 inhibitor +       | GLP-1 receptor agonist + | Insulin (basal) + |
|-------------------------|-------------------------|-------------------------|-------------------------|--------------------------|-------------------|
| TZD                     | SU                      | SU                      | SU                      | SU                       | TZD               |
| or DPP-4-i              | or DPP-4-i              | or TZD                  | or TZD                  | or TZD                   | or DPP-4-i        |
| or SGLT2-i              | or SGLT2-i              | or SGLT2-i              | or DPP-4-i              | or SGLT2-i               | or SGLT2-i        |
| or GLP-1-RA             | or GLP-1-RA             | or Insulin <sup>§</sup> | or GLP-1-RA             | or Insulin <sup>§</sup>  | or GLP-1-RA       |
| or Insulin <sup>§</sup> | or Insulin <sup>§</sup> |                         | or Insulin <sup>§</sup> |                          |                   |

If A1C target not achieved after approximately 3 months of triple therapy and patient (1) on oral combination, move to basal insulin or GLP-1 RA, (2) on GLP-1 RA, add basal insulin, or (3) on optimally titrated basal insulin, add GLP-1 RA or mealtime insulin. Metformin therapy should be maintained, while other oral agents may be discontinued on an individual basis to avoid unnecessarily complex or costly regimens (i.e., adding a fourth antihyperglycemic agent).

### Combination Injectable Therapy

(See Figure 8.2)

## LIFESTYLE MODIFICATION

(Including Medically Assisted Weight Loss)

Entry A1c < 7.5%

Entry A1c ≥ 7.5%

Entry A1c > 9.0%

### MONOTHERAPY\*

- ✓ Metformin
- ✓ GLP-1 RA
- ✓ SGLT-2i
- ✓ DPP-4i
- ✓ AGi
- ⚠ TZD
- ⚠ SU/GLN

If not at goal in 3 months proceed to Double Therapy

### DUAL THERAPY\*

**MET**  
or other  
1st-line  
agent

+

- ✓ GLP-1 RA
- ✓ SGLT-2i
- ✓ DPP-4i
- ⚠ TZD
- ⚠ Basal Insulin
- ✓ Colesevelam
- ✓ Bromocriptine QR
- ✓ AGi
- ⚠ SU/GLN

If not at goal in 3 months proceed to Triple Therapy

### TRIPLE THERAPY\*

**MET**  
or other  
1st-line  
agent +  
2nd-line  
agent

+

- ✓ GLP-1 RA
- ✓ SGLT-2i
- ⚠ TZD
- ⚠ Basal insulin
- ✓ DPP-4i
- ✓ Colesevelam
- ✓ Bromocriptine QR
- ✓ AGi
- ⚠ SU/GLN

If not at goal in 3 months proceed to or intensify insulin therapy

### SYMPTOMS

NO YES

DUAL  
Therapy

OR

TRIPLE  
Therapy

INSULIN  
±  
Other  
Agents

**ADD OR INTENSIFY  
INSULIN**

Refer to Insulin Algorithm

### LEGEND

- ✓ Few adverse events or possible benefits
- ⚠ Use with caution

\* Order of medications listed represents a suggested hierarchy of usage

PROGRESSION OF DISEASE →



# What would be the most appropriate discharge regimen

---

1. Continue Tresiba, Tradjenta and Actos and ask the patient to see his PCP ASAP
2. d/c Tresiba, but continue Tradjenta and Actos
3. d/c Tresiba, Tradjenta and Actos, start Novolg SS
- d/c Tresiba, Tradjenta and Actos, start Novolin N and metformin
5. d/c Tresiba, Tradjenta and Actos, start Novolin mix 70/30 and glimepiride



*Questions are guaranteed in life*  
*Answers aren't*